KALARIS THERAPEUTICS, INC. Investing Cash Flow
KALARIS THERAPEUTICS, INC. (KLRS) reported Investing Cash Flow of -$30.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $20.17M.
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$50.35M.
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $14.98M, a 199.66% increase year-over-year.
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2024-12-31 was $5.00M, a 80.17% decline year-over-year.
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$19.72M, a 120.76% decline from fiscal 2024.
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2024 was $95.00M, a 150.10% increase from fiscal 2023.
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2023 was $37.98M.
- KALARIS THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$80.48M, a 143.27% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$30.18M 10-Q · filed 2026-08-11 | -$15.20M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$50.35M 10-Q · filed 2026-05-12 | -$35.37M derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2025-12-31 | $14.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$19.72M 10-K · filed 2026-03-17 | ||
| 2025-09-30 | -$34.71M 10-Q · filed 2025-11-12 | |||
| 2024-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $25.00M derived: sum of 2 quarters · filed 2025-03-07 | $55.00M derived: sum of 3 quarters · filed 2025-03-07 | $95.00M 10-K · filed 2025-03-07 |
| 2024-09-30 | $20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $50.00M derived: sum of 2 quarters · filed 2024-11-12 | $90.00M 10-Q · filed 2024-11-12 | $115.22M derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-06-30 | $30.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $70.00M 10-Q · filed 2024-08-09 | $95.22M derived: sum of 3 quarters · filed 2025-03-07 | $28.37M derived: sum of 4 quarters · filed 2025-03-07 |
| 2024-03-31 | $40.00M 10-Q · filed 2024-05-13 | $65.22M derived: sum of 2 quarters · filed 2025-03-07 | -$1.63M derived: sum of 3 quarters · filed 2025-03-07 | $36.26M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-12-31 | $25.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$41.63M derived: sum of 2 quarters · filed 2025-03-07 | -$3.74M derived: sum of 3 quarters · filed 2025-03-07 | $37.98M 10-K · filed 2025-03-07 |
| 2023-09-30 | -$66.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$28.96M derived: sum of 2 quarters · filed 2024-11-12 | $12.77M 10-Q · filed 2024-11-12 | $26.30M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $37.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $79.62M 10-Q · filed 2024-08-09 | $93.16M derived: sum of 3 quarters · filed 2024-08-09 | $54.60M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $41.72M 10-Q · filed 2024-05-13 | $55.26M derived: sum of 2 quarters · filed 2024-05-13 | $16.70M derived: sum of 3 quarters · filed 2024-05-13 | $16.23M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $13.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$25.02M derived: sum of 2 quarters · filed 2024-03-15 | -$25.50M derived: sum of 3 quarters · filed 2024-03-15 | -$80.48M 10-K · filed 2024-03-15 |
| 2022-09-30 | -$38.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$39.04M derived: sum of 2 quarters · filed 2023-11-02 | -$94.02M 10-Q · filed 2023-11-02 | -$107.54M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$479.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$55.46M 10-Q · filed 2023-08-03 | -$68.98M derived: sum of 3 quarters · filed 2023-08-03 | -$14.01M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$54.98M 10-Q · filed 2023-05-04 | -$68.50M derived: sum of 2 quarters · filed 2023-05-04 | -$13.54M derived: sum of 3 quarters · filed 2023-05-04 | $66.18M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$13.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $41.44M derived: sum of 2 quarters · filed 2023-02-15 | $121.16M derived: sum of 3 quarters · filed 2023-02-15 | $185.98M 10-K · filed 2023-02-15 |
| 2021-09-30 | $54.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $134.68M derived: sum of 2 quarters · filed 2022-11-03 | $199.51M 10-Q · filed 2022-11-03 | $201.43M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $79.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $144.54M 10-Q · filed 2022-08-04 | $146.46M derived: sum of 3 quarters · filed 2022-08-04 | -$63.80M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $64.83M 10-Q · filed 2022-05-05 | $66.75M derived: sum of 2 quarters · filed 2022-05-05 | -$143.51M derived: sum of 3 quarters · filed 2022-05-05 | -$118.51M derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | -$208.34M derived: sum of 2 quarters · filed 2022-02-10 | -$183.34M derived: sum of 3 quarters · filed 2022-02-10 | -$169.50M 10-K · filed 2022-02-10 |
| 2020-09-30 | -$210.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | -$185.26M derived: sum of 2 quarters · filed 2021-11-05 | -$171.42M 10-Q · filed 2021-11-05 | -$136.54M derived: sum of 4 quarters · filed 2021-11-05 |
| 2020-06-30 | $25.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-06 | $38.84M 10-Q · filed 2021-08-06 | $73.72M derived: sum of 3 quarters · filed 2021-08-06 | $73.77M derived: sum of 4 quarters · filed 2021-08-06 |
| 2020-03-31 | $13.84M 10-Q · filed 2021-05-06 | $48.72M derived: sum of 2 quarters · filed 2021-05-06 | $48.76M derived: sum of 3 quarters · filed 2021-05-06 | |
| 2019-12-31 | $34.88M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $34.92M derived: sum of 2 quarters · filed 2021-02-12 | -$64.64M 10-K · filed 2021-02-12 | |
| 2019-09-30 | $46.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$99.52M 10-Q · filed 2020-11-10 | ||
| 2019-06-30 | -$99.57M 10-Q · filed 2020-09-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |